CAS 688309-70-8

BX430

CAS : 688309-70-8

BX430 is used for chronic pain and cardiovascular disease and it is a potent and selective noncompetitive allosteric human P2X4 receptor channels antagonist

Formule : C₁₅H₁₅Br₂N₃O

Degré de pureté : 97.34%

Couleur et forme : Solid

Masse moléculaire : 413.11

Ref: TM-T14844

BX 430

CAS : 688309-70-8

Formule : C₁₅H₁₅Br₂N₃O

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 413.1071

Ref: IN-DA00FHXU

BX430

CAS : 688309-70-8

BX430

Degré de pureté : ≥95%

Masse moléculaire : 413.11g/mol

Ref: 54-BUP10396

1-(2,6-Dibromo-4-Isopropylphenyl)-3-(Pyridin-3-Yl)Urea

CAS : 688309-70-8

1-(2,6-Dibromo-4-Isopropylphenyl)-3-(Pyridin-3-Yl)Urea

Degré de pureté : 98%

Masse moléculaire : 413.11g/mol

Ref: 54-OR1022959

1-(2,6-DIBROMO-4-ISOPROPYLPHENYL)-3-(PYRIDIN-3-YL)UREA

CAS : 688309-70-8

Degré de pureté : 98%

Masse moléculaire : 413.1130066

Ref: 10-F861435

BX 430

CAS : 688309-70-8

BX-430 is a potent and selective inhibitor of voltage-gated sodium channels, including Nav1.8, which is primarily expressed in the central nervous system. This molecule has been shown to inhibit bladder contractility in rat models. BX-430 inhibits uptake of cations through non-selective cations channels and blocks the activation of p2y receptors, leading to an increase in intracellular calcium levels. It has also been shown to have anti-inflammatory effects by inhibiting microglia activation and suppressing production of pro-inflammatory cytokines such as TNFα and ILβ.

Formule : C₁₅H₁₅Br₂N₃O

Degré de pureté : Min. 95%

Masse moléculaire : 413.11 g/mol

Ref: 3D-NCB30970